Today: 20 March 2026
Subscribe
Browse Category

Pharmaceuticals 11 October 2025 - 23 October 2025

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Holdings (SCNX) Stock Skyrockets on FDA Drug Launch – Will the Rally Last?

Scienture Holdings (NASDAQ: SCNX) jumped up to 45% in pre-market trading on Oct. 23, 2025, after announcing its first commercial sales of Arbli, the only FDA-approved ready-to-use liquid losartan. Trading volume surged to 77 million shares, far above its 4 million average. Despite the spike, SCNX remains down over 90% for the year. The company recently eliminated all debt by converting debentures to equity.
23 October 2025
··
Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Avadel Stock Rockets on $2.1B Alkermes Buyout Offer – Key Developments & Analyst Takeaways

Alkermes will acquire Avadel for $18.50 per share in cash, plus a $1.50 contingent payout, valuing the deal at about $2.1 billion. Avadel’s LUMRYZ sales are projected at $265–$275 million in 2025, with 3,100 patients on therapy. AVDL shares surged to near a 52-week high after the Jazz settlement and Alkermes news. Halper Sadeh LLC is investigating whether the offer undervalues Avadel.
22 October 2025
·····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk shares closed at $54.78 on Oct. 21, down nearly 50% in 2025 and wiping out about $70 billion in market value. The Novo Nordisk Foundation forced a board overhaul, with chair Helge Lund and six directors to be replaced. Novo announced deals to buy Akero for up to $5.2 billion and license Omeros’ OMS906 for up to $2.1 billion. U.S. price pressure and Eli Lilly’s competition have weighed on investor sentiment.
22 October 2025
··
Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences Stock Skyrockets on $200M Lifeline for Schizophrenia Drug

Minerva Neurosciences shares jumped over 150% on October 21, 2025, after announcing a private placement to raise up to $200 million led by Vivo Capital. The cash will fund a Phase 3 trial and FDA resubmission for its schizophrenia drug roluperidone. Trading volume surged to 39.5 million shares, and the stock hit a new 52-week high near $6.80. Market cap rose from under $20 million to about $48 million.
21 October 2025
··
iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio Stock Surges on Bullish Analyst Calls and Obesity Drug Breakthroughs

iBio (NASDAQ: IBIO) traded at $0.89 midday October 21, down 63% year-to-date from $2.45 in January. Shares jumped over 20% last week after bullish “Outperform” ratings from Oppenheimer and Leerink Partners, with price targets of $5.00 and $2.00. The company reported positive preclinical results for its obesity drug IBIO-610 and raised $50 million in a recent offering. Market cap stands near $18 million.
21 October 2025
·
SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

SPRO Stock Skyrockets on Breakthrough Oral Antibiotic Data

Spero shares closed at $2.29 on Oct. 20, 2025, up 3.6%, after reporting Phase 3 trial results showing oral tebipenem HBr matched IV imipenem in overall success (58.5% vs 60.2%) at IDWeek. The stock has surged over 120% year-to-date, trading between $0.51 and $3.22. GSK plans an FDA submission in Q4. Analyst 12-month targets average $5, but ratings remain mixed following a recent Zacks downgrade.
21 October 2025
···
AI Drug Discovery Darling? Recursion Pharma (RXRX) Stock’s Wild Ride in 2025

Recursion Pharma Stock Soars 16% on AI Buzz and Big Pharma Deals – Can RXRX Keep Climbing?

Recursion Pharmaceuticals shares jumped over 16% to $6.80 intraday on Oct. 20, capping a volatile month that saw a 44% gain and heavy trading volume. CEO Chris Gibson sold 100,000 shares on Oct. 10 for about $604,000, drawing analyst scrutiny. The company reported a Q2 net loss of $171.9 million on $19.2 million revenue. Recursion recently acquired Exscientia in a $630 million all-stock deal.
20 October 2025
··
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer shares surged 15% from $23.6 to $27.2 after announcing a Medicaid pricing deal with the Trump administration and agreeing to buy obesity drug developer Metsera for up to $7.3 billion. Q2 revenue rose 10% to $14.7 billion, beating estimates. Pfizer trimmed its dividend but still yields 6–7%. Analysts raised price targets to $29–30, citing the pricing pact and new drug prospects.
19 October 2025
·
Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics (RANI) Stock Surges 150% on $1B+ Chugai Collaboration – Analysts Weigh In

Rani Therapeutics shares surged over 150% on Oct. 17, 2025, after announcing a collaboration and license deal with Chugai Pharmaceutical worth up to $1.085 billion. The company also raised $60.3 million in PIPE financing, stating it now has funding into 2028. Trading volume spiked to 70 million shares, up from a 300,000 average. Analyst opinions remain split on the stock’s outlook.
18 October 2025
···
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Gilead Sciences stock jumped over 4% on Oct. 17, 2025, closing at $122.81 and hitting a new 52-week high. The surge follows a patent settlement extending exclusivity for Biktarvy until 2036 and FDA approval of Yeztugo, a new HIV prevention shot. Gilead’s market cap stands near $150 billion after a 47% year-to-date gain. Analysts remain bullish but note concerns over U.S. drug pricing pressures.
18 October 2025
···
Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Weight-Loss Drug Mania Shook Markets—Now Hims & Hers Bets on a Menopause Care Boom

Hims & Hers Health launched a menopause and perimenopause care program on its Hers platform Oct. 15, triggering a one-day stock surge of up to 16%. Shares quickly reversed, falling 11% to around $52–53 by Oct. 17. The company aims for $1 billion annual revenue in women’s health by 2026. Analysts remain divided, citing high valuation and volatile trading despite rapid revenue growth.
17 October 2025
·
Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Biotech Breakthrough: Rani Therapeutics (RANI) Stock Skyrockets on $1B Deal – What Investors Need to Know

Rani Therapeutics shares surged nearly 190% to $1.37 on Oct. 17, 2025, after announcing a pharma partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal includes $10 million upfront, development and sales milestones, and potential royalties. Rani also raised $60.3 million in a private placement, extending its cash runway into 2028. Trading volume spiked to several times the daily average.
17 October 2025
···
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly (LLY) Surges on Obesity Drug Boom and Alzheimer’s Breakthroughs – Is $1,000 Next?

Eli Lilly shares hit a record $832 intraday on Oct. 1, fueled by demand for its obesity drugs and Alzheimer’s advances, before slipping 4% after Donald Trump pledged to cut weight-loss drug prices. Lilly’s Mounjaro and ZepBound now hold 57% of U.S. GLP-1 prescriptions, outpacing Novo Nordisk. First-half 2025 revenue jumped about 40% year-on-year. Most analysts remain bullish, despite valuation and policy concerns.
17 October 2025
··
Novo Nordisk’s $5.2 Billion Bet to Reverse Fatty Liver Disease – Game-Changer or Big Gamble?

Novo Nordisk’s Weight-Loss Crown at Risk? NVO Stock Slumps Amid Surprise Deals – What’s Next

Novo Nordisk shares fell 6.7% in Copenhagen on Oct. 17, 2025, and U.S. pre-market quotes pointed to a further 4.8% drop. The stock has lost over 40% year-to-date, erasing hundreds of billions in value. Recent acquisitions and job cuts have not reversed investor caution, as competition from Eli Lilly intensifies and analysts warn of more profit downgrades.
17 October 2025
··
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines shares jumped 180% to $162 on Oct. 16 after its lead drug, ulixacaltamide, met all key endpoints in two Phase 3 trials for essential tremor. The rally added nearly $3 billion to the company’s market cap. Praxis announced a $525 million public offering to fund commercialization and pipeline expansion. Analyst price targets surged, with several now above $250.
17 October 2025
··
Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

Scienture (SCNX) Stock Skyrockets on New FDA-Approved Blood Pressure Drug Launch

SCNX shares jumped over 30% in early trading Oct. 16 after Scienture announced Arbli, the first FDA-approved ready-to-use liquid losartan, is now available through major wholesalers. The stock hit an intraday high of $1.12 before trading near $0.71 by mid-day. Scienture recently secured a major rebate deal to drive Arbli’s adoption. Analysts remain cautious, citing weak financials and high volatility.
16 October 2025
··
Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune (ADAP) Sees Wild Stock Surge Amid Cash Crunch – Biotech Turnaround or Last Gasp?

Adaptimmune Therapeutics shares surged 42% on October 8, 2025, after nearly doubling intraday on September 19, despite no major news and record trading volumes. The company sold its key T-cell therapy programs, including Tecelra, to US WorldMeds for $55 million upfront to pay off debt and avoid insolvency. Q2 net loss reached $30.3 million, with cash reserves at $26 million by mid-year. Analysts remain bearish, with no major buy ratings.
16 October 2025
··
Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Menopause Launch Sends Hims & Hers (HIMS) Stock Soaring – What’s Next?

Hims & Hers shares jumped 16% on Oct. 15 after launching a menopause care program, trading near $62.80 on Oct. 16, up 7% for the day. The stock has more than doubled in 2025, far outpacing rivals like Teladoc. Regulatory scrutiny from the FDA and FTC triggered brief sell-offs in September. Analyst sentiment remains cautious, with most price targets in the high $30s despite recent gains.
16 October 2025
··
1 … 34 35 36 37 38

Stock Market Today

  • Cocoa Prices Fall on Strong Dollar and Improved West African Supply
    March 20, 2026, 2:22 PM EDT. Cocoa prices dropped sharply as May ICE NY cocoa fell 1.86% to a two-week low, pressured by a stronger U.S. dollar and improved supply prospects. Consistent rains in Ivory Coast and Ghana have boosted cocoa pod development, easing supply concerns. ICE cocoa inventories are at a 7.5-month high of 2.31 million bags, reflecting ample stockpiles. Despite recent demand signals with local grinders in Ivory Coast increasing contract purchases, price cuts by Ghana and Ivory Coast farmers-major suppliers producing over half the world's cocoa-limit price gains. Additional pressure comes from weak global demand evidenced by falling sales volumes and reduced cocoa grinding in key regions including Europe and Asia. Meanwhile, higher Nigerian exports further soften prices.
Go toTop